Eteplirsen

2016's Most Hyped Events: How Did It Work Out For The Stocks?
New Aetna Clinical Policy Bulletin Details 'Medical Necessity' Of Sarepta's Exondys 51
Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment
New Aetna Clinical Policy Bulletin Details 'Medical Necessity' Of Sarepta's Exondys 51
Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment
Sarepta Shares Fall After Anthem Blue Cross Finds Issue With Eteplirsen
Sarepta's Deal With Summit Could Be More About European Eteplirsen Approval Expectations

Eteplirsen Recent News

Sarepta Prices Newly-Approved DMD Drug, Cowen Upgrades Stock To Outperform
2022 Will Bring New Questions For Sarepta; Jefferies Raises Price Target From $7 To $50
Jefferies Examines The Effect Of Sarepta's Drug Approval On PTC Therapeutics
Sarepta Analysts Turn Bullish After Duchenne Muscular Dystrophy Drug Eteplirsen Gets Approval
Oppenheimer Raises Sarepta's Target From $60 To $76
William Blair Sees An End To Sarepta's Regulatory Saga, Upgrades And Lifts Price Target To $88
Biotech's 'New Sweetheart': Janney Upgrades Sarepta To Buy
Sarepta's Eteplirsen Receives Accelerated FDA Approval, Shares Soar 80%
SunTrust On Sarepta Therapeutics: FDA Likely To Deny Approval For Eteplirsen
Farkas' FDA Departure Could Signal 'Imminent Decision' For Eteplirsen
JMP On Sarepta: 'We Maintain Our 10% Chance Of First-Cycle Approval For Eteplirsen'
Exclusive: Dr. Ron Farkas, Eteplirsen's Harshest Critic, Has Left The FDA
Downside Risk In Sarepta Shares Greater Than Upside Potential, Janney Says
Wedbush Bullish On Sarepta's Eteplirsen Data
Drug Trial Extension By FDA Doesn't Change Baird's Outlook On Sarepta
What's The Deal With Sarepta?
Tuesday's Top 6 Pre-Market Gainers Explained
Wedbush Upgrades Sarepta To Outperform As 'FDA Comes Up With Option C'
Why Did Sarepta Therapeutics Plunge 20%?
Sarepta Therapeutics Says FDA Will Not Complete Eteplirsen Review By PDUFA Date; Stock Surges
Strange Price Action In Sarepta Therapeutics
Sarepta Therapeutics Surges 20% On No News
Sarepta Spikes 20%, Feuerstein Says Company Can Win FDA Drug Approval